CLYDE YAN: Open Payments
NPI 1922558865 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,001 in 126 payments from 19 companies in 2025. Trend: 2023 $2,135 · 2024 $2,098 · 2025 $2,001
Food & beverage: $1,994Education: $8
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 27 | $317 |
| Neurocrine BioSciences, Inc. | 16 | $235 |
| Otsuka America Pharmaceutical, Inc. | 15 | $227 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $181 |
| Janssen Pharmaceuticals, Inc | 11 | $179 |
| Vanda Pharmaceuticals Inc. | 6 | $167 |
| Axsome Therapeutics, Inc. | 10 | $141 |
| Collegium Pharmaceutical, Inc. | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Corium, LLC | 5 | $64 |
Products named: Qelbree, INGREZZA, REXULTI, CAPLYTA, SPRAVATO, HETLIOZ, Auvelity, Jornay PM.
Industry payments across IN — which companies pay providers there.
